Eligibility & Clinical Context
BMI eligibility, baseline labs, candidacy, comorbidities, research foundations, and novel agents. Browse the pillar guide and 21 supporting RenewMD education articles in this cluster.
Begin Eligibility ReviewSee Plans & Pricing
Pillar guide
Supporting articles (21)
- How Labs Fit Into a Safe Weight Management Plan
- GLP-1 Receptor Agonists and Cardiovascular Health: What Studies Show
- GLP-1 Medications After Bariatric Surgery: Clinical Considerations
- Type 2 Diabetes and GLP-1 Weight Management: The Dual Benefit
- GLP-1 Receptor Agonists and Healthy Aging: Emerging Research
- GLP-1 and Addictive Behaviors: What Emerging Research Shows
- GLP-1 Therapy and Liver Health: NAFLD, MASLD, and Metabolic Research
- Non-Stimulant Weight Loss Medication: A New Era of Treatment
- Why Baseline Lab Work Matters in Medical Weight Loss
- Comparing GLP-1 Receptor Agonist Efficacy for Weight Management
- GLP-1 Therapy and Fatty Liver Disease (NAFLD): What the Research Reveals
- Can GLP-1 Therapy Reduce Chronic Inflammation? What the Science Says
- GLP-1 Therapy and Brain Health: Early Research on Alzheimer's and Dementia
- Can GLP-1 Therapy Help with Brain Fog? What Patients Report and What Science Shows
- GLP-1 Therapy, ADHD, and Executive Function
- GLP-1 Immunogenicity and Anti-Drug Antibodies
- Retatrutide: The Triple-Agonist Frontier
- Orforglipron: The Future of Oral GLP-1 Therapy
- GLP-1 Therapy and Chronic Pain Conditions
- GLP-1 Therapy for Hypothalamic Obesity
- GLP-1 Therapy and Lipedema